Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer

Overview of attention for article published in Journal of Clinical Oncology, January 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 5 news outlets
twitter: 14 X users

bluesky: 1 Bluesky user

Readers on

mendeley: 16 Mendeley

So far, Altmetric has seen 5 news stories from 5 outlets.

Postoperative RT Plus Cetuximab Showed Mixed Results in Head and Neck Cancer Trial

Pediatric News , 03 Feb 2025

TOPLINE: Adding cetuximab (C) to postoperative radiotherapy (RT) improves disease-free survival (DFS) but not overall survival (O…

How Radiotherapy with cetuximab could also be superior to radiotherapy alone for sufferers who endure surgical procedure for head, neck most cancers – healthmedicinet

Health Medicinet, 28 Jan 2025

Results from the Phase III NRG Oncology RTOG 0920 (NRG-RTOG 0920) trial assessing postoperative radiotherapy with or with out…

Radiotherapy with cetuximab may be superior to radiotherapy alone for patients who undergo surgery for head, neck cancer

MedicalXpress, 27 Jan 2025

Results from the Phase III NRG Oncology RTOG 0920 (NRG-RTOG 0920) trial assessing postoperative radiotherapy with or without…

Radiotherapy Plus Cetuximab Tops Solo in Head, Neck Cancer

Mirage News, 24 Jan 2025

Recent results from the phase III NRG Oncology RTOG 0920 (NRG-RTOG 0920) trial assessing postoperative radiotherapy with or…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.